Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01411800 | An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects | PHASE1 | COMPLETED | 28 | — | — | Aug 1, 2011 | May 1, 2012 | Jul 20, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 500 mg LX1033, capsules administered two times per day orally |
| Treatment B | EXPERIMENTAL | 500 mg LX1033, tablets administered two times per day orally |
| Name | Type | Description |
|---|---|---|
| 250 mg capsule | DRUG | Two 250 mg capsules will be administered for 500 mg dose |
| 250 mg tablets | DRUG | Two 250 mg tablets will be administered for a 500 mg dose |
Inclusion Criteria: * Adult subjects age 18 to 55 years * Vital signs acceptable at Screening * Body mass index (BMI) between 18 and 35 kg/m\^2 at Screening * Considered to be in good health, as determined by the Investigator * Normal ECG findings * Negative urine screen for drugs of abuse and nega...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ardelyx, Inc. | ARDX | 4 | PHASE3 | Tenapanor |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | — | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | NA | Undisclosed |